Clinical Scorecard: Impact of Granulocyte Colony-Stimulating Factor on Adverse Effects Following CAR T Cell Treatment for Lymphoma and Myeloma
At a Glance
Category
Detail
Condition
Lymphoma and multiple myeloma treated with CAR T cell therapy
Key Mechanisms
CAR T cells induce immune toxicities (CRS, ICANS) and hematologic toxicity; G-CSF stimulates neutrophil recovery but may affect myeloid activation and cytokine release
Target Population
Adults ≥18 years with relapsed/refractory lymphoma or multiple myeloma receiving commercial or investigational CAR T therapy
Care Setting
Specialized oncology centers administering CAR T cell therapy
Key Highlights
CAR T therapy offers deep responses but is associated with immune toxicities (CRS, ICANS) and prolonged cytopenias.
G-CSF is used to expedite neutrophil recovery post-chemotherapy but its optimal use post-CAR T is unclear due to potential exacerbation of CRS and ICANS.
Current guidelines and institutional policies vary; tisagenlecleucel recommends avoiding growth factors until 3 weeks post-CAR T or CRS resolution.
Guideline-Based Recommendations
Diagnosis
Use ASTCT consensus criteria to grade CRS and ICANS based on clinical parameters.
Assess lymphoma and myeloma response using International Working Group and International Myeloma Working Group criteria respectively.
Management
Avoid G-CSF until at least 3 weeks post-CAR T or until CRS has resolved (per tisagenlecleucel package insert).
Consider institutional policies for G-CSF use; prophylactic versus reactive administration strategies remain investigational.
Monitor for and manage CRS and ICANS per established clinical protocols.
Monitoring & Follow-up
Monitor temperature, blood pressure, oxygenation, fluid and vasopressor use for CRS grading.
Assess neurological status including ICE scores, consciousness, seizures, and neuroimaging for ICANS grading.
Track neutrophil counts daily to identify onset and recovery from neutropenia.
Risks
Potential exacerbation of CRS and ICANS with G-CSF due to stimulation of myeloid cells and cytokine release.
Prolonged hematologic toxicity influenced by lymphodepleting chemotherapy and CAR T inflammatory effects.
Infection risk associated with neutropenia post-CAR T therapy.
Patient & Prescribing Data
Adults with relapsed/refractory lymphoma or multiple myeloma treated with commercial or investigational CAR T therapies.
G-CSF use post-CAR T is variable; prophylactic pegylated G-CSF prior to CAR T has been used but effects on toxicity and outcomes are not well defined. Data are retrospective and hypothesis-generating.
Clinical Best Practices
Apply standardized grading criteria (ASTCT) for CRS and ICANS to guide clinical decisions.
Delay G-CSF administration until CRS resolution or at least 3 weeks post-CAR T to minimize risk of exacerbating immune toxicities.
Individualize G-CSF use based on patient neutropenia severity, institutional protocols, and emerging evidence.
Closely monitor hematologic recovery and signs of infection during post-CAR T period.
Conduct prospective studies to clarify optimal timing and safety of G-CSF in CAR T recipients.
by Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
